Form 4: United Therapeutics EVP Exercises Share Tracking Awards Under 10b5-1 Plan
SEC Form 4 Filing
Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised share tracking awards for 7,700 shares under a pre-arranged 10b5-1 plan.
Summary
- Paul A. Mahon, the EVP & General Counsel of United Therapeutics Corp, executed a transaction involving share tracking awards on September 19, 2024.
- The transaction involved the exercise of 7,700 share tracking awards at a price of $163.30.
- These awards were exercised under a pre-arranged 10b5-1 plan established on June 20, 2024.
- Following the transaction, Mahon directly owns 36,710 shares of Common Stock and 83,550 share tracking awards.
- Share tracking awards are non-dilutive cash-settled stock appreciation rights that can only be settled in cash and cannot be converted into common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment about the company's prospects.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. The use of a 10b5-1 plan indicates that the transactions were pre-planned and intended to avoid accusations of insider trading. Many companies use share tracking awards as part of their executive compensation packages.
Comparison to Industry Standards
- Share tracking awards are similar to stock appreciation rights (SARs) and are used by many companies in the biotechnology and pharmaceutical industries, including companies like Amgen, Gilead Sciences, and Biogen.
- These instruments are designed to align executive compensation with company performance without diluting existing shareholders, a common goal in the industry.
- The use of 10b5-1 plans is a standard practice among corporate executives to manage the sale or purchase of company stock while mitigating the risk of insider trading allegations.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it involves cash-settled stock appreciation rights and does not dilute existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/13/2016 | Date share tracking awards became exercisable |
| 06/20/2024 | Date the 10b5-1 plan was entered into by the reporting person |
| 09/19/2024 | Date of the transaction (exercise of share tracking awards) |
| 09/23/2024 | Date of signature on the Form 4 filing |
| 03/13/2025 | Expiration date of share tracking awards |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.